Psychiatric NP Scope of Practice for ADHD in Michigan

You’re a psychiatrist or psychiatric nurse practitioner who wants to treat ADHD patients via telehealth. Maybe you’re joining a platform like Klarity, or you’re setting up your own virtual practice. The big question: Can you legally prescribe Adderall, Ritalin, and other Schedule II stimulants through video visits?

The short answer in 2026: Yes — but with important caveats that vary by state.

Federal COVID-era flexibilities that allowed telehealth prescribing of controlled substances have been extended through December 31, 2026. That means you can evaluate a new ADHD patient over video and initiate stimulant treatment without an in-person visit, as long as you follow DEA rules and your state allows it.

But there’s a catch: permanent federal rules are coming in 2027, likely requiring a special DEA telemedicine registration. And state laws create a patchwork — what flies in California might get you in trouble in Texas.

This guide breaks down exactly what you need to know to prescribe ADHD medications via telehealth legally and confidently in 2026, with state-by-state rules for California, Texas, Florida, New York, Pennsylvania, and Illinois.

Federal Telehealth Prescribing Rules: Where We Stand in 2026

The Ryan Haight Act (Pre-2020)

Before COVID-19, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 made telehealth ADHD treatment nearly impossible. The law required an in-person medical evaluation before any provider could prescribe a controlled substance. No exceptions for video visits, no matter how thorough your assessment.

A psychiatrist couldn’t legally start a patient on Adderall after even the most comprehensive telehealth evaluation — federal law demanded that physical exam first.

COVID Changed Everything (2020–2026)

In March 2020, the DEA exercised emergency authority to waive the in-person exam requirement. Suddenly, providers could prescribe Schedule II stimulants via live video visits to new patients, as long as the prescription met legitimate medical standards.

That emergency flexibility was supposed to end when the Public Health Emergency ended in May 2023. But recognizing that millions of ADHD patients and thousands of providers relied on telehealth access, the DEA kept extending it.

As of January 2026, the DEA and HHS announced their fourth extension — telehealth prescribing of controlled substances (including ADHD medications) is legal through December 31, 2026. You can continue prescribing stimulants via video without an initial in-person visit, following the same rules that have been in place since 2020.

Requirements during this extension period:

• Live audio-video interaction (not just phone calls for initial visits)
• Legitimate medical purpose and proper evaluation
• Standard controlled substance protocols (DEA registration, e-prescribing, state PDMP checks)
• Documentation meeting the standard of care

What’s Coming: Permanent DEA Rules (2027+)

The DEA is finalizing three new telemedicine rules to replace the temporary extensions. Based on January 2025 announcements, here’s what to expect:

Telemedicine Special Registration: The DEA will create a new registration pathway specifically for telehealth providers who want to prescribe controlled substances without in-person exams. This registration will come with requirements:

• Mandatory nationwide PDMP (Prescription Drug Monitoring Program) checks
• Strict patient identity verification during video visits
• Likely additional compliance standards

The good news: This preserves telehealth access for ADHD treatment long-term. The DEA isn’t reverting to the old ‘in-person exam always required’ model.

Established Patient Exception: If you’ve seen a patient in person at least once (or they’ve been seen by another provider in your practice), you can continue telehealth treatment without additional restrictions. This exception helps hybrid practices.

Platform Registration: For the first time, telehealth companies (not just individual providers) will need to register with the DEA. This adds corporate-level oversight to prevent ‘pill mill’ behavior but shouldn’t affect individual providers practicing on legitimate platforms.

The DEA abandoned its early 2023 proposal that would have limited initial telehealth prescriptions to just 30 days of stimulants. After 38,000+ public comments from providers and patients, they went back to the drawing board. The final rules should be more practical for ongoing ADHD care.

What you should do now: Continue prescribing under current rules through 2026. Start planning for the special registration requirement — when it becomes available (likely late 2026 or early 2027), you’ll want to obtain it to ensure uninterrupted prescribing authority.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Telehealth ADHD Prescribing Rules

Federal law sets the baseline, but state laws determine your scope of practice. What matters:

1. Does your state allow telehealth prescribing of controlled substances?
2. What’s your prescriptive authority as a psychiatrist vs PMHNP?
3. Are there PDMP requirements, supply limits, or collaboration mandates?

Let’s break down the six states where most telehealth ADHD providers practice.

California: Telehealth-Friendly with Expanding NP Independence

Can you prescribe ADHD meds via telehealth? Yes, with no state-imposed restrictions beyond federal law.

Key rules:

• No in-person exam required: California Business & Professions Code §2242 explicitly states that an ‘appropriate prior examination’ can be conducted via telehealth — even asynchronous methods if clinically appropriate. A thorough video evaluation meets the standard for prescribing stimulants.
• PDMP mandatory: You must check California’s CURES database before the initial prescription and at least every 4 months for ongoing Schedule II stimulant therapy. Non-negotiable.
• E-prescribing required: All controlled substances must be prescribed electronically (with rare exceptions).

Scope of practice:

Psychiatrists (MD/DO): Full authority. If you have a California medical license and DEA registration, you can evaluate ADHD patients via video and prescribe stimulants on day one.

Psychiatric Nurse Practitioners: California is transitioning to Full Practice Authority (FPA) for experienced NPs through AB 890 (passed 2020).

• New NPs: Must practice under physician supervision/collaboration initially
• Experienced NPs: After completing 4,600 hours (roughly 3 years) of supervised practice and meeting training requirements, you can apply for independent practice authority (effective 2023–2026 rollout)
• By 2026, qualifying PMHNPs can prescribe ADHD medications independently via telehealth without physician oversight

Licensing: You must hold a California license — no telehealth registration or compact shortcuts. Out-of-state providers need to get a full CA license, which can take 4–6 months.

Bottom line for California: One of the most telehealth-friendly states. Just ensure you’re checking CURES regularly and document your evaluations thoroughly. If you’re an NP, understand where you fall on the supervision-to-independence spectrum.

Texas: Physician-Only ADHD Prescribing (NPs Are Out)

Can you prescribe ADHD meds via telehealth? Yes if you’re a physician. No if you’re a nurse practitioner or PA.

Key rules:

• Telehealth allowed for mental health: Texas permits telemedicine prescribing for psychiatric conditions. No state ban on teleprescribing stimulants for ADHD (the state’s ‘no telehealth for chronic pain’ rule doesn’t apply to ADHD).
• But here’s the kicker: Texas Board of Nursing regulations prohibit APRNs and PAs from prescribing Schedule II controlled substances in outpatient settings. Period.

The only exceptions are hospital inpatient orders (≥24-hour stays), hospice care, or emergency department orders. Outpatient ADHD treatment doesn’t qualify.

What this means practically:

• Psychiatrists: Full prescribing authority via telehealth. Use video evaluation, meet standard of care, prescribe as needed.
• PMHNPs: You can evaluate the patient and manage non-medication aspects of care, but only a physician can write the Adderall prescription. You need a collaborating MD/DO to sign off on all Schedule II stimulant prescriptions.
• This isn’t about collaboration — it’s a hard prohibition on NP prescribing of Schedule IIs for outpatients.

PDMP: Texas requires PMP checks for opioids, benzodiazepines, barbiturates, and carisoprodol — but not legally mandated for stimulants. Still recommended as best practice.

E-prescribing: Mandatory for all controlled substances in Texas (as of 2021, HB 2174).

Licensing: Texas is part of the Interstate Medical Licensure Compact (IMLC), so out-of-state physicians can expedite getting a Texas license. But you still need the full license — no telehealth workaround.

Bottom line for Texas: If you’re a psychiatrist, Texas is workable. If you’re an NP hoping to treat ADHD patients in Texas via telehealth platforms, you’ll need physician oversight for every stimulant prescription. This is the most restrictive state in our list for NP ADHD practice.

Florida: Explicitly Allows Telehealth ADHD Prescribing (With Protocol Requirements for NPs)

Can you prescribe ADHD meds via telehealth? Yes — Florida law has a specific exception for psychiatric disorders.

Key rules:

• Psychiatric exception: Florida Statutes §456.47 generally prohibits prescribing Schedule II controlled substances via telehealth EXCEPT for: (1) treatment of psychiatric disorders, (2) inpatient care, (3) hospice, or (4) nursing facility care. ADHD qualifies as a psychiatric disorder, so you’re explicitly permitted to prescribe stimulants via telehealth.
• No in-person exam required by state law for mental health treatment.
• PDMP mandatory: You must check Florida’s E-FORCSE database before prescribing controlled substances to patients age 16+. Document that you reviewed it.

Scope of practice:

Psychiatrists: Full authority with a Florida license and DEA registration.

Psychiatric Nurse Practitioners:

• Florida allows APRNs to prescribe controlled substances (as of 2017 law changes)
• 7-day limit: Generally, APRNs can prescribe Schedule II substances for only a 7-day supply for acute conditions
• BUT — ‘Psychiatric Nurse’ Exception: If you’re a PMHNP (defined as an APRN with an advanced psych degree and 2+ years post-grad clinical experience under a psychiatrist), the 7-day limit does NOT apply. You can prescribe ongoing stimulant refills.
• Supervision required: Florida psychiatric NPs must practice under a written protocol agreement with a supervising psychiatrist. You’re not independent — the psychiatrist doesn’t need to co-sign every prescription, but the oversight relationship must exist.
• For treating minors with mental health medications, you must have a consulting pediatrician or psychiatrist on your protocol.

Licensing:

• You need a Florida license OR can use Florida’s out-of-state telehealth registration (unique to Florida)
• Out-of-state providers can register with Florida DOH to provide telehealth services to FL patients without getting a full license
• Requirements: active unrestricted license in your home state, clean 5-year disciplinary record, malpractice insurance
• Important: Out-of-state registrants can prescribe controlled substances ONLY if they fall under the same exceptions (psychiatric care qualifies)
• You’ll still need to register with Florida’s PDMP

This registration option makes Florida attractive for multi-state telehealth practice.

Bottom line for Florida: Clear legal framework. Psychiatrists have straightforward authority. PMHNPs need a supervising psychiatrist in their protocol but aren’t limited to 7-day supplies for ADHD meds. The out-of-state registration is a real advantage for expanding your practice.

New York: Recently Aligned State Law with Federal Telehealth Rules

Can you prescribe ADHD meds via telehealth? Yes, as of May 2025 update.

Key rules:

• May 2025 regulation update: New York State DOH updated 10 NYCRR §80.63 to explicitly allow controlled substance prescribing via telehealth when consistent with federal law. Translation: As long as the DEA extension is in effect (through 2026), NY permits it.
• PDMP mandatory — strictly enforced: You must check New York’s I-STOP/PMP registry before prescribing ANY Schedule II, III, or IV controlled substance. For ADHD stimulants, check it every time. NY has robust enforcement of this requirement.
• E-prescribing mandatory: New York required electronic prescribing of all controlled substances since 2016. No paper prescriptions.
• 90-day supply option: New York allows prescribing up to a 90-day supply of stimulants for ADHD if you note the condition code ‘B’ (for ADHD/minimal brain dysfunction) on the prescription. This is unusual and helpful for stable patients — reduces monthly refill hassle.

Scope of practice:

Psychiatrists: Full independent authority.

Psychiatric Nurse Practitioners:

• After 3,600 hours of clinical practice (roughly 2 years full-time), PMHNPs can practice independently without a written collaborative agreement
• Still must maintain a ‘collaborative relationship’ with a physician (doesn’t require supervision or approval)
• Can prescribe Schedule II–V controlled substances with DEA registration and NYS narcotic license number
• No state-specific quantity limits on NP stimulant prescribing — same authority as physicians
• Must complete one-time CE on pain management/addiction (primarily opioid-focused)

Licensing: You must hold a New York license. NY is not part of IMLC for physicians, and no telehealth registration shortcut exists. Full licensure required.

Bottom line for New York: Favorable environment post-May 2025 regulatory update. Experienced NPs have essentially the same prescribing authority as psychiatrists. The 90-day supply option and clear state alignment with federal rules make this a strong state for ADHD telehealth. Just stay on top of mandatory PDMP checks.

Pennsylvania: Telehealth-Permitted with NP Collaboration Requirements

Can you prescribe ADHD meds via telehealth? Yes, following federal rules.

Key rules:

• No state telehealth ban: Pennsylvania has no statute prohibiting controlled substance prescribing via telemedicine. State medical boards permit establishing patient relationships through telehealth if standard of care is met.
• PDMP required: You must check Pennsylvania’s PDMP before the initial prescription of any controlled substance in a new course of treatment. For opioids/benzos, check every time. For stimulants, required at start and recommended periodically.
• E-prescribing mandatory: Act 96 of 2018 required electronic prescribing of controlled substances (effective October 2019).

Scope of practice:

Psychiatrists: Full authority with PA license and DEA registration. Pennsylvania is part of IMLC, making it easier for out-of-state psychiatrists to get licensed.

Nurse Practitioners (CRNPs):

• Collaborative agreement required: PA is a restricted-practice state. CRNPs must have a supervising physician collaborator.
• 30-day limit on Schedule II: CRNPs can prescribe Schedule II controlled substances for up to a 30-day supply only. Any continuation beyond 30 days requires physician approval.
• For Schedule III/IV substances, up to 90-day supply allowed.
• Monthly physician review: The collaborating physician must review the NP’s Schedule II prescribing monthly to ensure appropriate management.

Practically for ADHD: Your PMHNP can evaluate the patient and write the initial one-month Adderall prescription. Before refilling for month two, the collaborating psychiatrist needs to review the case and approve continuation. The psychiatrist doesn’t need to see the patient directly, but must be in the loop.

Bottom line for Pennsylvania: Workable for telehealth with proper structure. If you’re a solo PMHNP, you’ll need a PA-licensed psychiatrist as your collaborator and can’t prescribe stimulants beyond 30 days without their involvement. Psychiatrists practice independently. The state’s embrace of telepsychiatry (especially for rural/underserved areas) makes this a growing market.

Illinois: Full Practice Authority Possible for Experienced NPs

Can you prescribe ADHD meds via telehealth? Yes, state law permits it.

Key rules:

• Telehealth parity: Illinois updated its Telehealth Act in 2021 (HB 3308) to ensure telehealth access. No state ban on controlled substance prescribing via telemedicine.
• Illinois Controlled Substance License required: In addition to your medical/nursing license and DEA registration, you need a separate Illinois CS license to prescribe controlled substances in IL. Apply through IL DFPR.
• PDMP: State law mandates documenting PMP access for opioid prescriptions and initial benzos. Not explicitly required for stimulants, but recommended best practice.

Scope of practice:

Psychiatrists: Full independent authority.

Nurse Practitioners — Two Tiers:

1. APRNs Under Collaboration:

• Must have written collaborative agreement with physician
• Can prescribe Schedule II for 30-day supply only
• Any continuation beyond 30 days requires collaborating physician’s approval
• Physician must conduct monthly review of the NP’s Schedule II prescribing

2. Full Practice Authority (FPA) APRNs:

• Available after completing 4,000 hours of practice under collaboration AND 250 hours of continuing education
• FPA-certified APRNs can practice and prescribe independently — no physician collaboration required for most medications
• Key for ADHD: The law requires physician consultation only for Schedule II narcotic drugs (opioids) and benzodiazepines. Stimulants (amphetamine, methylphenidate) are Schedule II non-narcotic controlled substances, so FPA NPs can prescribe them independently without physician oversight.
• Must still have IL CS license and DEA registration

This is significant: An experienced PMHNP in Illinois with FPA certification has the same ADHD prescribing authority as a psychiatrist via telehealth.

Licensing: Illinois is part of IMLC for physicians (easier out-of-state licensing). APRNs need full IL license plus the IL CS license.

Other: Illinois allows ‘Prescribing Psychologists’ with physician collaboration, but they cannot prescribe Schedule II stimulants (excluded from their formulary). ADHD medication management remains with MD/DO, APRNs, or PAs.

Bottom line for Illinois: Favorable for telehealth with clear FPA pathway for experienced NPs. If you’re a new PMHNP, you’ll work under collaboration with 30-day limits initially. Once you hit FPA status, you’re independent for ADHD prescribing. Illinois’s recent telehealth mandates (requiring insurance parity and 50% telepsychiatry access for Medicaid) create a supportive environment.

State Telehealth Prescribing Comparison Table

Practical Compliance: What You Must Do to Prescribe ADHD Meds via Telehealth

Beyond understanding whether it’s legal, here’s what compliance actually looks like:

1. Proper Clinical Evaluation

Even though you can prescribe via video, you can’t cut corners on the assessment. Your telehealth ADHD evaluation must meet the same standard of care as in-person:

• Use live audio-video for initial evaluations (not just phone calls)
• Conduct a thorough clinical interview covering DSM-5-TR criteria for ADHD
• Review medical history, previous diagnoses, prior medication trials
• Screen for substance use disorders, cardiac risk factors, other contraindications
• For pediatric patients: involve parents/guardians, gather collateral information (school reports if available)
• Document everything thoroughly — your notes should demonstrate you met the standard for prescribing a controlled substance

Some states explicitly warn against prescribing based solely on online questionnaires without real-time interaction. A video visit is not optional.

2. State PDMP Checks

Nearly every state requires checking the Prescription Drug Monitoring Program before prescribing controlled substances. State-specific requirements:

• California: Check CURES before initial Rx and every 4 months ongoing
• Texas: Not mandated for stimulants but recommended
• Florida: Check E-FORCSE before prescribing to patients ≥16
• New York: Check I-STOP before EVERY Schedule II prescription (strictly enforced)
• Pennsylvania: Check PA PDMP at start of treatment and periodically
• Illinois: Document PMP check for initial controlled substance prescriptions

Why this matters: PDMP reviews reveal if your patient is getting stimulants from multiple providers, has a history of controlled substance abuse, or has risk factors you need to address. It’s both a legal requirement and essential clinical practice.

Document in your chart that you reviewed the PDMP and your clinical interpretation (e.g., ‘PDMP reviewed — no concerning patterns identified; patient not receiving controlled substances from other providers’).

3. Electronic Prescribing

All six states require or strongly encourage e-prescribing of controlled substances:

• Mandatory: California, Texas (since 2021), Florida, New York (since 2016), Pennsylvania (since 2019)
• Illinois: Required as of recent regulations

You’ll need EPCS (Electronic Prescribing of Controlled Substances) certification and software that meets DEA requirements (two-factor authentication, secure transmission).

No calling in stimulant prescriptions. No paper prescriptions (except rare emergencies). Get set up with a compliant e-prescribing system before you start.

4. DEA Registration in Patient’s State

You must have a DEA registration that covers the state where the patient is located when receiving care.

If you’re licensed in California and treating a patient via telehealth who’s in Florida, you need:

• Florida medical license (or FL telehealth registration)
• DEA registration listing a Florida practice location

Some providers use their primary DEA registration and add additional state locations as needed. Work with your DEA liaison to ensure compliance.

5. Informed Consent and Documentation

While not always statutorily required, obtaining informed consent for telehealth treatment is best practice (and required in some states like Florida):

• Explain telehealth modality and any limitations
• Discuss privacy/security measures
• Provide information for emergency follow-up if needed
• For controlled substances, discuss risks, benefits, monitoring plan
• Document consent in the medical record

For minors, ensure parent/guardian consent for both telehealth treatment and psychotropic medication use.

6. Collaboration Agreements (For NPs)

If you’re an NP in Pennsylvania, Illinois (without FPA), Florida, or Texas (though TX prohibits your Schedule II prescribing anyway), ensure your collaborative agreement:

• Names your supervising/collaborating physician
• Specifies scope of controlled substance prescribing authority
• Outlines review/consultation protocols
• Meets your state’s specific requirements (monthly review, 30-day approval, etc.)

Keep this documentation updated and accessible for any board audits.

The Business Reality: Why Telehealth ADHD Care Makes Sense for Your Practice

Understanding the regulations is critical, but let’s talk about why providers are building telehealth ADHD practices despite the compliance complexity.

Patient Demand Is Massive

ADHD is one of the most common psychiatric conditions:

• 6.1 million children (9.8%) diagnosed with ADHD in the U.S.
• 4.4% of adults (over 10 million people) have ADHD
• Most are undertreated — less than 30% of adults with ADHD receive treatment

The provider shortage is severe. Average wait time to see a psychiatrist in many markets: 6–8 weeks or longer. For ADHD-specialized providers, even longer.

Telehealth solves the access problem. You can see patients across your entire state (or multiple states if you’re multi-licensed), dramatically expanding your potential patient base beyond your immediate geographic area.

Better Schedule Flexibility and Income Potential

Telehealth ADHD medication management is efficient:

• Initial evaluations: 45–60 minutes
• Follow-ups: 15–30 minutes (typically monthly initially, then can extend to quarterly for stable patients)
• No commute time between appointments
• You control your schedule completely

Many providers see 15–25 patients per day via telehealth vs. 8–12 in traditional office settings. The efficiency gain is real.

Revenue models:

• Insurance-based: Most insurance plans cover telehealth psychiatry at parity with in-person. ADHD medication management typically reimburses $80–150 for follow-ups, $200–300 for initial evaluations.
• Cash-pay: Self-pay rates for ADHD telehealth range from $150–300 for initial visits, $75–150 for follow-ups.

On a platform like Klarity, you see pre-qualified patients matched to your availability. You’re not spending time and money on marketing or patient acquisition — you pay only when you see patients (standard listing fee per completed visit).

Compare that to DIY practice building where you’re spending $3,000–5,000/month on:

• Google Ads at $15–40 per click for ‘ADHD psychiatrist’ keywords
• SEO that takes 6–12 months before generating leads
• Psychology Today listings ($30–50/month competing with hundreds of other providers)
• Zocdoc or directory fees plus per-booking charges
• Staff time handling inquiries, scheduling, qualifying leads
• No-show rates from cold leads

The all-in patient acquisition cost for most DIY marketing: $200–500+ per booked patient. And that’s after months of testing, optimization, and wasted ad spend on clicks that never convert.

Platforms eliminate that gamble. You get qualified patient flow without upfront marketing spend. The economics work better for most providers, especially when building or scaling a practice.

Clinical Satisfaction: Treating Patients Who Need You

ADHD is highly treatable. Stimulant medications are effective for 70–80% of patients when properly prescribed and managed. You see real, measurable improvement in patients’ lives — better work performance, improved relationships, reduced anxiety.

For many patients, getting an ADHD diagnosis and effective treatment via telehealth is life-changing after years of struggling. That clinical impact matters.

The telehealth modality also reduces barriers for ADHD patients specifically:

• Scheduling flexibility works better for people with executive function challenges
• Video visits from home reduce ‘forgetting appointments’
• Text/app-based appointment reminders improve adherence
• Easier for working adults who can’t take time off for in-person visits

You’re meeting patients where they are — often literally and figuratively.

Common Questions: ADHD Telehealth Prescribing FAQs

Q: Can I prescribe Adderall or Vyvanse via telehealth in 2026?

A: Yes, through December 31, 2026 under the federal DEA/HHS extension. You must use live video for evaluation, have proper state licensure and DEA registration, and follow your state’s PDMP and e-prescribing requirements. After 2026, new permanent DEA rules will likely require a special telemedicine registration but should continue to allow telehealth ADHD prescribing.

Q: Do I need to see ADHD patients in person eventually?

A: Not under current federal rules (through 2026). Once you establish care via telehealth, you can continue managing the patient remotely indefinitely as long as it meets the standard of care. Some providers choose to offer in-person visits for patients who want them or have complex situations, but there’s no legal requirement for periodic in-person exams during the current extension period.

Pending DEA rules may create exceptions for ‘established patients’ (anyone seen in-person once by you or your practice), but this isn’t finalized yet.

Q: What if I’m an NP in a state that limits my ADHD prescribing?

A: Your options depend on the state:

• Texas: You cannot prescribe Schedule II stimulants to outpatients. You’d need to work with a collaborating physician who writes the prescriptions, or focus on non-medication ADHD management.
• Pennsylvania or Illinois (without FPA): You can prescribe but are limited to 30-day supplies with physician approval for continuation. Work within a collaborative practice model where a psychiatrist reviews cases monthly.
• Florida: Ensure you have a supervising psychiatrist protocol in place. You can prescribe ongoing stimulant therapy as a psychiatric nurse.
• California or New York: Work toward full practice authority (CA’s transitional independence, NY’s 3,600-hour threshold) to prescribe independently.

Consider getting multi-state licenses in states with better NP scope of practice if you want more autonomy.

Q: How do I check the PDMP in multiple states?

A: Most states have online PDMP portals requiring provider registration:

• Register separately in each state where you practice
• Some states participate in interstate PDMP data sharing (e.g., RxCheck, PMP Interconnect), allowing you to see some out-of-state data
• Budget 5–10 minutes per new patient to review PDMP data thoroughly
• Many EHR systems are integrating PDMP queries directly (check if yours offers this)

Q: Can I use audio-only (phone) visits for ADHD medication management?

A: Initial evaluations must use audio-video under current DEA guidance. The Ryan Haight waiver specified ‘two-way interactive audio-video communication.’

For follow-up visits with established patients, some states/payers allow audio-only in certain circumstances (especially post-COVID expansions), but this varies. Check your state telehealth parity laws. Best practice: default to video for controlled substance prescribing to stay compliant with federal rules.

Q: What happens if the DEA doesn’t finalize permanent rules by December 31, 2026?

A: The DEA has repeatedly extended flexibilities to avoid disruption. Most expect either another extension or expedited final rules before year-end 2026. Monitor DEA announcements closely in Q4 2026.

If there’s a lapse: providers would need to comply with the original Ryan Haight Act (in-person exam required), which would be hugely disruptive. The DEA and HHS have strong incentive to prevent this scenario.

Q: Do I need malpractice insurance that covers telehealth?

A: Yes. Verify your malpractice policy explicitly covers telemedicine/telehealth practice. Most modern policies include it, but some older policies may exclude it or require a rider. Also ensure coverage in all states where you’re licensed and practicing.

Q: How do I handle prescribing for pediatric ADHD patients via telehealth?

A: Same legal framework applies, with additional considerations:

• Obtain parent/guardian consent for both telehealth treatment and medication
• Have parent/guardian present during video evaluation (best practice, sometimes required by state for minors)
• Gather collateral information (teacher reports, prior evaluations)
• More frequent monitoring (monthly initially) due to growth/development factors
• Some state NP collaboration agreements require physician involvement for pediatric psychotropic meds (check your state)

Q: Can I prescribe ADHD medications for patients in states where I’m not licensed?

A: No. You must be licensed in the state where the patient is physically located during the telehealth visit. If a patient travels to another state, they cannot receive care from you unless you’re licensed there.

Exception: Florida’s out-of-state telehealth registration allows limited practice for FL patients without full licensure.

Interstate compacts (IMLC for physicians, NLC for RNs) can expedite licensing but don’t eliminate the requirement.

Getting Started: Joining Klarity’s ADHD Telehealth Network

If you’re a psychiatrist or PMHNP interested in treating ADHD patients via telehealth without the headache of building your own patient acquisition and compliance infrastructure:

What Klarity provides:

• Pre-qualified ADHD patients matched to your specialty and availability
• Integrated telehealth platform (HIPAA-compliant

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care